12:05 PM EST - Immunoprecise Antibodies Ltd. : Is collaborating in a multi-company effort with the laboratory of Dr. Frederick Dyda at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH), and Dr. M. Javad Aman at Integrated Biotherapeutics (IBT), to better understand the molecular binding interactions of potential therapeutic antibody candidates resulting from IPA's SARS-CoV-2 programs aimed at treating or preventing COVID-19. Immunoprecise Antibodies Ltd.
shares V.IPA are trading down $0.06 at $1.52.
